Commercialization

Perth – November 01, 2026 -- Orthocell Limited (ASX: OCC) sold 92 units of its Remplir nerve repair wrap in the U.S. in October 2026, generating AU$279,000 in revenue, an 84% increase on the average monthly sales of 50 units in Q1 FY27.

It is the strongest month of U.S. sales since the product launched. The company released the figures ahead of its Annual General Meeting on 6 November 2026. Standard quarterly reporting will continue after the meeting.

Surgeon adoption and distributor reach drive the October uplift

Orthocell attributes the result to four factors: growing surgeon adoption, increasing repeat use, a larger base of actively selling distributor representatives and broader hospital access across key U.S. markets. Remplir is a collagen nerve wrap for the repair and protection of peripheral nerves. It is FDA-cleared and manufactured by Orthocell in Australia.

Waltham – October 19, 2026 -- Lumicell, Inc. has promoted Chief Commercial Officer Marnie Curbow to Chief Executive Officer, effective immediately, less than a year after she joined the fluorescence-guided cancer surgery company.

Curbow rose from VP of Sales to CEO within roughly 12 months

Curbow joined Lumicell in October 2025 as Vice President of Sales. She was then promoted to Chief Commercial Officer, with responsibility for sales, marketing, reimbursement and clinical applications. Lumicell credits her with building its commercial organization and strengthening its go-to-market strategy.

Before Lumicell, she served as GM & VP Sales Diagnostics for the Americas at Rhinomed, where she launched a novel diagnostic and secured a SPARK accelerator award from BARDA. She brings nearly two decades of experience across breast oncology, surgery, diagnostics and therapeutics.

San Diego – October 19, 2026 -- eGlint, Inc. won the $250,000 Grand Prize at the 2026 BioTools Innovator Capstone Competition on October 14, giving the rapid-proteomics developer fresh capital as it moves its first product, ProteoMix, toward commercialization.

eGlint beat three other finalists, Caravel, Pando Bioscience and QuantumCyte, in a live competition. The four were drawn from the 30-company 2026 accelerator cohort, which was selected from more than 550 applicants worldwide. Attendees, including life science executives, investors and strategic partners, decided the winner by live audience vote.

Bridgewater – – October 19, 2026 -- Insmed (Nasdaq: INSM) has launched BRINSUPRI Tablets 25 mg (brensocatib hydrate) in Japan, making it the first and only approved, commercially available treatment for non-cystic fibrosis bronchiectasis (NCFB) in the country.

Japan's health ministry cleared the once-daily oral tablet in August 2026

The Ministry of Health, Labour, and Welfare approved BRINSUPRI based on results from the Phase 3 ASPEN study. The label covers adults and pediatric patients aged 12 years and older.

Samuele Butera, Insmed's Senior Vice President and General Manager, Global Respiratory, called the launch "a meaningful step forward for the bronchiectasis community." Makoto Nakamura, Senior Vice President and General Manager, Japan, said the company will focus on providing information to healthcare professionals and promoting proper use of the therapy.

Boston – October 17, 2026 -- AdvaMed is steering its more than 400 small and emerging medtech members toward The MedTech Conference, October 18–21 in Boston, where it expects over 4,000 attendees and 1,800 companies.

JC Scott, who has returned to the trade association as Chief Strategy Officer, also leads AdvaMed Accel as Executive Director. Accel is the association's dedicated division for emerging members, offering advocacy, access and community.

Partnering platform compresses investor outreach into days

Full Access attendees and Full Access exhibitors can use the Partnering platform to book one-on-one meetings with investors, collaborators, potential customers and strategic partners. Scott says conversations that might otherwise take months to arrange can happen over a few days. AdvaMed has published a 2026 investor list for preview.

Woodbridge – October 15, 2026 -- P2 Science, Inc. has appointed Brian Freedman, a marketer with more than 15 years of experience, as Vice President, Marketing and Communications as the green chemistry company scales commercialization of its sustainable ingredient portfolio.

Freedman takes charge of brand, product marketing and communications across three business lines

Freedman will lead brand strategy, product marketing, go-to-market planning and corporate communications across P2 Science's personal care, flavor and fragrance, and performance materials businesses. The company is also deepening its relationships with customers in the beauty and consumer products industries.

Dallas – October 14, 2026 -- Nanoscope Therapeutics has appointed Troy Short, who built the global supply chain for Zolgensma across more than 30 countries at AveXis, as Senior Vice President of Manufacturing and Supply Chain while its lead gene therapy MOGENRY is under regulatory review in the United States and Japan.

Short takes charge of GMP manufacturing, commercial supply and global distribution

Short will lead Nanoscope's GMP manufacturing, commercial supply and global distribution strategy as the company moves toward potential approval and launch of MOGENRY (sonpiretigene isteparvovec; MCO-010). He has more than 20 years of operations and supply chain experience in pharmaceuticals and gene therapy.

His stated priorities are strengthening manufacturing partnerships, building a resilient commercial supply chain and ensuring product availability to patients and physicians upon potential approval.

Sydney – October 07, 2026 -- First Graphene Limited has secured its first purchase order from US-based Flux Footwear, marking the Australian graphene producer's maiden commercial entry into the global sports shoe market, valued at more than US$150 billion.

Flux Footwear becomes third client to adopt PureGRAPH in growing footwear portfolio

Flux will incorporate First Graphene's PureGRAPH into its athletic and leisure footwear line, targeting strength and durability upgrades for the brand's Graphene XT performance gym shoes. PureGRAPH will progressively replace Flux's existing graphene formulations as production volumes increase, following recent joint development work between the two companies.

Zagreb – September 16, 2026 -- Pony.ai and Verne have begun fully driverless Robotaxi test rides with passengers on public roads in Zagreb, marking the first such deployment in Europe.

Driverless rides now run a 22-kilometer route in Zagreb

The route connects Verne's headquarters and a main business district with Franjo Tuđman Airport Zagreb. Pony.ai and Verne plan to expand fully driverless coverage over the coming months to encompass the entire operating area in Zagreb.